MPH
Dr Taqueti: A diabetic woman with a history of stable ischemic heart disease presents with escalating exertional angina and a markedly decreased exercise tolerance. Although her symptoms are progressive, an acute coronary syndrome must be excluded. Additional causes of chest pain, including pulmonary embolism, vascular dissection, myocarditis/pericarditis, tachyarrhythmia, structural heart disease, coronary and esophageal spasm, and anemia, should be considered. 
Patient presentation (continued)
:
Dr Taqueti:
This patient has CAD with prior revascularization and multiple cardiac comorbidities, which place her at a high pretest probability for progression of ischemic heart disease. She has no evidence of acute myocardial injury and no signs of decompensated heart failure. Nonetheless, she is obese with suboptimally controlled hypertension, diabetes mellitus, and low-density lipoprotein cholesterol, along with anemia, chronic kidney disease, and obstructive sleep apnea. Despite a preserved LV ejection fraction, she has LV hypertrophy and diastolic dysfunction. Although recent vasodilator stress testing with single-photon emission computed tomography imaging was reported to be normal, important caveats may limit the sensitivity of this test for diagnosing ischemia in the higher-risk, symptomatic patient. These include technical issues such as caffeine intake resulting in ineffective vasodilator stress, or diagnostic limitations such as decreased sensitivity for detecting ischemia, particularly in the presence of diffuse or multivessel CAD (leading to diminished ability to detect relative perfusion defects, so-called balanced ischemia). After stable renal function is confirmed, nonurgent diagnostic coronary angiography with fractional flow reserve assessment would be reasonable to evaluate for progression of epicardial CAD and resultant flow-limiting ischemia. respectively, demonstrated that her epicardial coronary plaques have not progressed to flow-limiting stenoses and are therefore unlikely to explain her symptoms. Transient coronary vasospasm may coexist with nonobstructive plaque but is less likely to be responsible for this patient's progressive exertional angina with minimal rest symptoms. Although her plaques are nonobstructive, she has diffuse atherosclerosis in the presence of obesity, diabetes mellitus, and diastolic dysfunction, all of which are associated with small vessel disease and coronary microvascular dysfunction (CMD).
The small vessels of the coronary circulation cannot be imaged directly, either invasively or noninvasively, and have not been a traditional focus of cardiovascular management. With increasing use of advanced imaging techniques such as stress cardiac positron emission tomography and possibly cardiac magnetic resonance imaging, absolute blood flow integrated over the entire coronary circulation (eg, from epicardial to microvascular vessels) can be quantified during stress and rest, and their ratio can be calculated into a coronary flow reserve (CFR). Observational data have shown that impaired CFR identifies patients at risk independently of traditional factors, including LV dysfunction, ischemia, hypertension, obesity, and diabetes mellitus. Together with standard semiquantitative myocardial perfusion, ventricular function, and ECG data, quantitative myocardial blood flows and CFR may be useful to diagnose global small vessel ischemia in this patient, which could explain her angina, provide further risk stratification, and potentially guide further therapy. 
This patient has mild regional ischemia visible on semiquantitative perfusion imaging, corresponding to typical territories of the distal posterior descending artery and septal perforator branches. However, there is also some evidence of transient ischemic dilatation and severely reduced stress myocardial blood flows and reserve. These are high-risk findings that have been associated with worse cardiovascular prognosis, including greater risk of death, even without concomitant obstructive CAD. This patient has stable ischemic heart disease and severely impaired CFR, likely from a combination of diffuse atherosclerosis and small vessel ischemia from associated CMD.
Currently, there are no therapies specifically targeting CMD, and the evidence base for its management is lacking. As in her counterpart with obstructive CAD, this patient requires aggressive medical therapy and risk factor reduction, including more optimal management of blood pressure, lipids, weight, glycemia, and obstructive sleep apnea, with an age-appropriate workup for anemia. Beyond this, objective testing provides diagnostic and prognostic clarification, which may help to avoid costly and potentially harmful additional testing in this patient, and to better define disease to develop future tailored management for patients like this one. Efforts are ongoing to more precisely phenotype individuals with nonobstructive CAD and CMD, many of whom are women, to determine which interventions may be effective. Newer therapies targeting residual cholesterol and inflammatory risk, neurohormonal activation, glucose handling in the kidneys, and even surgical weight loss, may demonstrate improved outcomes in this sector of patients.
Patient presentation (continued):
Lisinopril was added and hydralazine was discontinued. Carvedilol was used in place of labetalol. Isosorbide therapy was continued but with an extendedrelease formulation at 240 mg daily. Rosuvastatin was increased to 40 mg daily. Nutrition, exercise, and weight-loss counseling was provided. She was discharged from the hospital with improved blood pressures and decreased exertional angina. An overnight polysomnography study was arranged for continuous positive airway pressure therapy titration. Strategies for improved glycemic management, including bariatric surgery, were discussed with the patient and her endocrinologist. She was ultimately started on empagliflozin, a sodium- glucose cotransporter 2 inhibitor. Three months later, her symptoms of intermittent exertional angina were better controlled, allowing her to be more active with improved quality of life. She was screened for inclusion in the National Heart, Lung, and Blood Institute-sponsored CIRT (Cardiovascular Inflammation Reduction Trial) and CIRT-CFR, but despite being a diabetic with stable ischemic heart disease, she did not meet inclusion criteria for obstructive multivessel CAD and was not enrolled. Dr Taqueti: This case illustrates some of the current challenges but also exciting prospects ahead for the diagnosis and management of patients with ischemia and no obstructive CAD (INOCA). As evident here, this represents a significant unmet need, particularly prevalent among female patients with heart disease. Defining CAD not only as an anatomic problem but also as a functional one, for which modern tools can be leveraged in future clinical trials to interrogate the full extent of the coronary circulation, may lead us to a more complete understanding of the pathobiology of ischemic heart disease with the goal of improving outcomes for all.
CASES AND TRACES

DISCUSSION
The clinical evaluation of symptomatic patients, particularly women, with stable ischemic heart disease can be challenging because of their varying clinical presentations, clinical risk factor burden, high degree of comorbidity, and increased risk of major ischemic heart disease events. This case illustrates a clinical scenario not infrequently encountered in clinical practice but one for which our understanding of the relevant disease pathophysiology, diagnosis, prognosis, and management is evolving with emerging data. 1 In doing so, it highlights the following points for discussion.
First, INOCA is common and may be present in up to 50% of symptomatic patients referred for evaluation of suspected CAD. It can occur in both women and men, although it is more prevalent in women. [2] [3] [4] It can also occur in patients with a history of obstructive CAD who may have persistent symptoms despite adequate revascularization. As such, it requires a high index of suspicion and access to an adequate diagnostic toolbox. Patients can be referred without much benefit for costly repeated testing with traditional approaches lacking sensitivity for diagnosis of small vessel disease. Some patients may even be asked to discontinue ostensibly appropriate therapies because of apparently normal results (ie, "clean coronaries") or abnormal testing perceived to represent false-positive findings.
Second, INOCA is associated with elevated cardiovascular morbidity and mortality, particularly in women, 4 and is highly comorbid with common conditions such as hypertension, diabetes mellitus, and obesity. These patients are at increased risk for adverse cardiovascular events, including acute coronary syndromes; heart failure with preserved ejection fraction 5 ; and death resulting from plaque erosion, impaired coronary vasoreactivity, and microvascular dysfunction with resultant ischemia.
Finally, despite its prevalence and associated cardiovascular risk, many questions remain unanswered, particularly in terms of patient management. As in the patient presented here, this may be especially relevant in patients with adequately revascularized but residual (nonobstructive) CAD who may already be on reasonable guidelinedirected medical therapies for secondary prevention, and for whom coronary revascularization is not an option for symptomatic improvement or ischemic burden reduction. 4 There are no effective therapies specifically targeting CMD, and trials with agents such as calcium channel blockers and ranolazine have been disappointing. Ongoing efforts are focused on defining the distinct clinical syndrome of INOCA and identifying current knowledge gaps and next steps for developing evidence-based therapies.
CONCLUSIONS
In patients with refractory angina despite optimal revascularization, CMD may be the culprit. This case illustrates the challenges associated with diagnosing and managing patients with INOCA, an increasingly recognized clinical syndrome with associated poor prognosis for which previous management approaches have led to underwhelming results, and for which new evidencebased approaches are needed.
